Andy Forreryd wins a "Best Abstract Presentation Price" about GARD technique

Andy Forreryd of the Dept. of Immunotechnology won a "Best Abstract Presentation Price" at the Oral Abstract session entitled Risk factors and biomarkers in occupational allergy held at EAACI 2015 in Barcelona. 

Andy's contribution was entitled Prediction of chemical respiratory sensitizers using GARD, a novel in vitro assay based on a genomic biomarker signature.

Andy Forreryd is a researcher at the Dept. of Immunotechnology at Lund University and a contributor to the R&D team connected to SenzaGen who’s research is the foundation for the GARD test products.

SenzaGen congratulates Andy and we are very proud to see that his great achievements as a researcher is getting acknowledged.


About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.